Maurice Karrenbrock

Maurice Karrenbrock

Auto-generated profile, based on publicly available information

Maurice Karrenbrock

School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, CH-1206 Geneva, CH

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2024 in The Journal of Physical Chemistry Letters
Verified
Journal Article
Open access
MKMaurice Karrenbrock
Maurice Karrenbrock
ABAlberto Borsatto
Alberto Borsatto
VRValerio Rizzi
Valerio Rizzi
DLDominykas Lukauskis
Dominykas Lukauskis
SASimone Aureli
Simone Aureli
FGFrancesco Luigi Gervasio
Francesco Luigi Gervasio
The calculation of absolute binding free energies (ABFEs) for protein-ligand systems has long been a challenge. Recently, refined force fields and algorithms have improved the quality of the ABFE calculations. However, achieving the level of accuracy required to inform drug discovery efforts remains difficult. Here, we present a transferable enhanced sampling strategy to accurately calculate absolute binding free energies using OneOPES with simple geometric collective variables. We tested the strategy on two protein targets, BRD4 and Hsp90, complexed with a total of 17 chemically diverse ligands, including both molecular fragments and drug-like molecules. Our results show that OneOPES accurately predicts protein-ligand binding affinities with a mean unsigned error within 1 kcal mol-1 of experimentally determined free energies, without the need to tailor the collective variables to each system. Furthermore, our strategy effectively samples different ligand binding modes and consistently matches the experimentally determined structures regardless of the initial protein-ligand configuration. Our results suggest that the proposed OneOPES strategy can be used to inform lead optimization campaigns in drug discovery and to study protein-ligand binding and unbinding mechanisms.

7 February 2024 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
MKMaurice Karrenbrock
Maurice Karrenbrock
VRValerio Rizzi
Valerio Rizzi
PPPiero Procacci
Piero Procacci
FGFrancesco Luigi Gervasio
Francesco Luigi Gervasio

27 July 2021
Verified
Journal Article
Open access
MMMarina Macchiagodena
Marina Macchiagodena
MKMaurice Karrenbrock
Maurice Karrenbrock
MPMarco Pagliai
Marco Pagliai
PPPiero Procacci
Piero Procacci
We describe a step-by-step protocol for the computation of absolute dissociation free energy with GROMACS code and PLUMED library, which exploits a combination of advanced sampling techniques and nonequilibrium alchemical methodologies. The computational protocol has been automated through an open source python middleware (HPC-Drug) which allows to set up the GROMACS/PLUMED input files for execution on high performing computing facilities. The proposed protocol, by exploiting its inherent parallelism and the power of the GROMACS code on graphical processing units, has the potential to afford accurate and precise estimates of the dissociation constants in drug-receptor systems described at the atomistic level. The procedure has been applied to the calculation of the absolute dissociation free energy of PF-07321332, an oral antiviral proposed by Pfizer, with the main protease (3CLpro) of SARS-CoV-2.

27 July 2021
Verified
Journal Article
Open access
MMMarina Macchiagodena
Marina Macchiagodena
MKMaurice Karrenbrock
Maurice Karrenbrock
MPMarco Pagliai
Marco Pagliai
PPPiero Procacci
Piero Procacci
We describe a step-by-step protocol for the computation of absolute dissociation free energy with GROMACS code and PLUMED library, which exploits a combination of advanced sampling techniques and nonequilibrium alchemical methodologies. The computational protocol has been automated through an open source python middleware (HPC-Drug) which allows to set up the GROMACS/PLUMED input files for execution on high performing computing facilities. The proposed protocol, by exploiting its inherent parallelism and the power of the GROMACS code on graphical processing units, has the potential to afford accurate and precise estimates of the dissociation constants in drug-receptor systems described at the atomistic level. The procedure has been applied to the calculation of the absolute dissociation free energy of PF-07321332, an oral antiviral proposed by Pfizer, with the main protease (3CLpro) of SARS-CoV-2.

28 February 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
MKMaurice Karrenbrock
Maurice Karrenbrock
PPPiero Procacci
Piero Procacci
FGFrancesco Luigi Gervasio
Francesco Luigi Gervasio
In this paper we further develop a combined Hamiltonian replica exchange / non-equilibrium alchemical method for absolute binding free energies and test its performance on 11 ligands of the BRD4 bromodomain protein. We compare the results obtained with our approach with those obtained with other equilibrium and non-equilibrium alchemical methods showing their relative strengths, weaknesses, and limits. We show how using an enhanced sampling technique, before the alchemical transformations, allows to get accurate estimates of the binding free energies even when starting with sub-optimal initial binding poses (e.g. from docking). We also study the effect of different restraining mechanisms on the final result, and introduce a new "Loose-Tight" restraining algorithm. The method proves to strike a good balance between ease of use, automation, speed, and accuracy for absolute ligand binding free energy calculations and our scripts make it easy to integrate it into pre-existing computational drug discovery pipelines.

1 August 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
MKMaurice Karrenbrock
Maurice Karrenbrock
ABAlberto Borsatto
Alberto Borsatto
VRValerio Rizzi
Valerio Rizzi
DLDominykas Lukauskis
Dominykas Lukauskis
SASimone Aureli
Simone Aureli
FGFrancesco Luigi Gervasio
Francesco Luigi Gervasio
The calculation of absolute binding free energies (ABFEs) for protein-ligand systems has long been a challenge. Recently, refined force fields and algorithms have improved the quality of ABFE calculations. However, achieving the level of accuracy required to inform drug discovery efforts remains difficult. Here, we present a transferable enhanced sampling strategy to accurately calculate absolute binding free energies using OneOPES with simple geometric collective variables. We tested the strategy on two protein targets, BRD4 and Hsp90, complexed with a total of 17 chemically diverse ligands, including both molecular fragments and drug-like molecules. Our results show that OneOPES accurately predicts protein–ligand binding affinities with a mean unsigned error within 1 kcal mol-1 of experimentally determined free energies, without the need to tailor the collective variables to each system. Furthermore, our strategy effectively samples different ligand binding modes, and consistently matches the experimentally determined structures regardless of the initial protein-ligand configuration. Our results suggest that the proposed OneOPES strategy can be used to inform lead optimization campaigns in drug discovery and to study protein-ligand binding and unbinding mechanisms.